Progress of carbapenem-resistant Klebsiella pneumoniae infection in neonates
Klebsiella pneumoniae is a common opportunistic pathogen capable of causing various types of infec-tions.In recent years,its drug resistance has been increasingly growing,especially with the widespread use of car-bapenem-based antibiotics,leading to an escalating prevalence of Carbapenem-Resistant Klebsiella pneumoniae(CRKP),which has become a pressing issue.Due to the complex resistance mechanisms of CRKP and the many limitations of drug use during the neonatal period,the selection of antimicrobial agents for CRKP infections in ne-onates is particularly challenging.The strategies of antimicrobial drugs application is different depending on the different resistance mechanisms of CRKP.Currently available drugs include the reutilization of some traditional an-tibiotics(such as colistin and tigecycline)and the development of new drugs(such as ceftazidime/avibactam and meropenem/vaborbactam).Experience with these drugs in neonates is limited,and there are no clear guidelines for their use.This article reviews the epidemiology,resistance mechanisms,and antimicrobial choices for CRKP infections in neonates,aiming to assist neonatologists in better understanding CRKP and more effectively treating CRKP infections in neonates.
万方数据
维普
